MicroRNA-218、microRNA-193b在宫颈癌组织中的表达及与化疗耐药性的关系

Expressions of miR-218 and miR-193b in cervical cancer tissues and their relationship with chemotherapy resistance

摘要:

目的 探讨microRNA-218（miR-218）、microRNA-193b（miR-193b）在宫颈癌组织中的表达及其与化疗耐药性的关系。方法 选取2018年1月—2023年1月成都医学院第一附属医院收治的101例行手术治疗的宫颈癌患者。患者均行紫杉醇、顺铂、阿霉素、5-氟尿嘧啶、卡铂药物敏感性试验，采用实时荧光定量聚合酶链反应检测miR-218、miR-193b表达情况。比较癌组织、癌旁组织中miR-218、miR-193b表达情况，统计化疗药物耐药情况，分析宫颈癌组织中miR-218、miR-193b的表达与化疗耐药性的关系。结果 癌组织中miR-218相对表达量低于癌旁组织（P <0.05），miR-193b相对表达量高于癌旁组织（P <0.05）。宫颈癌患者行体外化疗药物紫杉醇、顺铂、阿霉素、5-氟尿嘧啶、卡铂的耐药率分别为38.61%、46.53%、48.51%、26.73%和40.59%。宫颈鳞癌与宫颈腺癌患者对体外化疗药物紫杉醇、顺铂、阿霉素、5-氟尿嘧啶、卡铂耐药率比较，差异均无统计学意义（P >0.05）。耐药患者癌组织中miR-218相对表达量均低于敏感患者，miR-193b相对表达量均高于敏感患者（P <0.05）。受试者工作特征曲线分析结果显示，miR-218、miR-193b及两者联合预测宫颈癌患者化疗耐药性的敏感性分别为74.51%（95% CI：0.601，0.852）、70.59%（95% CI：0.560，0.821）、82.35%（95% CI：0.686，0.911），特异性分别为74.00%（95% CI：0.594，0.849）、78.00%（95% CI：0.637，0.880）、90.00%（95% CI：0.774，0.963），曲线下面积分别为0.754（95% CI：0.661，0.847）、0.743（95% CI：0.643，0.843）、0.890（95% CI：0.824，0.956）。结论 宫颈癌组织中miR-218表达低于癌旁组织、miR-193b表达高于癌旁组织，miR-218、miR-193b的表达水平与宫颈癌患者化疗耐药性有关，两者联合预测宫颈癌患者化疗耐药性效能良好。

Abstract:

Objective To investigate the expressions of miR-218 and miR-193b in cervical cancer tissues and their relationship with chemotherapy resistance.Methods A total of 101 patients with cervical cancer admitted to our hospital from January 2018 to January 2023 for surgical treatment were selected. All patients received drug sensitivity tests for paclitaxel, cisplatin, doxorubicin, 5-fluorouracil and carboplatin. The expressions of miR-218 and miR-193b were detected by quantitative real-time polymerase chain reaction and were compared in cancer tissues and adjacent tissues. The resistance to chemotherapy was recorded, and the relationship between the expressions of miR-218 and miR-193b in cervical cancer tissues and chemotherapy resistance was analyzed.Results The relative expression of miR-218 in cancer tissues was lower than that in adjacent tissues (P < 0.05), and the relative expression level of miR-193b was higher than that in adjacent tissues (P < 0.05). In patients with cervical cancer, the drug resistance rates of paclitaxel, cisplatin, doxorubicin, 5-fluorouracil and carboplatin were 38.61%, 46.53%, 48.51%, 26.73% and 40.59%, respectively. There was no significant difference in the drug resistance rates of paclitaxel, cisplatin, doxorubicin, 5-fluorouracil and carboplatin between patients with squamous cell carcinoma and adenocarcinoma (P > 0.05). The relative expression of miR-218 was lower and that of miR-193b was higher in patients with drug-resistant cervical cancer compared with those with drug-sensitive cervical cancer (P < 0.05). Receiver operating characteristic (ROC) curve analysis revealed that the sensitivities of miR-218, miR-193b and their combination for predicting chemotherapy resistance in patients with cervical cancer were 74.51% (95% CI: 60.09%, 85.23%), 70.59% (95% CI: 55.98%, 82.09%), and 82.35% (95%CI: 68.64%, 91.13%), with the specificities being 74.00% (95% CI: 59.39%, 84.92%), 78.00% (95% CI: 63.67%, 88.01%), and 90.00% (95% CI: 77.41%, 96.26%), and the areas under the curves being 0.754 (95% CI: 0.661, 0.847), 0.743 (95% CI: 0.643, 0.843) and 0.890 (95% CI: 0.824, 0.956).Conclusions The expression of miR-218 is lower and that of miR-193b is higher in cervical cancer tissues than in adjacent tissues. The expressions of miR-218 and miR-193b were related to chemotherapy resistance in patients with cervical cancer. The combination of the two indicators is effective in predicting chemotherapy resistance in patients with cervical cancer.